secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001213900-23-094535
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics terminates CEO James Cullem, appoints Thomas Jensen as CEO
--------------------------------------------------------------------------------

- James Cullem terminated as CEO and all other positions on December 8, 2023.
- Thomas Jensen appointed CEO effective December 8, 2023; previously SVP of Investor Relations and IT.
- Jensen co-founded Allarity Therapeutics A/S in 2004 and leads the Denmark laboratories.
- Audit committee entered consulting agreement with Dr. Jeremy R. Graff for R&D advisory on small molecule inhibitors.
- No material plan or arrangement yet in place for new CEO's compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/0001213900-23-094535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/ea189774-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-094535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer